Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
RUTHERFORD, N.J., Dec. 1, 2014 (GLOBE NEWSWIRE) -- Cancer Genetics, Inc. (Nasdaq:CGIX) ("CGI" or "the Company"), an emerging leader in DNA-based cancer diagnostics, announced today that it will...
-
TORONTO, ON--(Marketwired - November 29, 2014) - Grand Challenges Canada, funded by the Government of Canada, today announced $1.2 million in funding for 11 new global health innovations implemented...
-
Next Generation Sequencing (Genome/Exome sequencing/DNA sequencing) Global market - Forecast to 2020
Dublin, Nov. 28, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/2msswk/next_generation) has announced the addition of the "Next Generation Sequencing...
-
Dublin, Nov. 28, 2014 (GLOBE NEWSWIRE) -- Research and Markets (http://www.researchandmarkets.com/research/3ht8j8/stem_cell) has announced the addition of the "Stem Cell Research Products:...
-
SAN DIEGO, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Vical Incorporated (Nasdaq:VICL) today announced that the company will provide an overview of its technologies, development programs, and outlook on...
-
IRVING, Texas, Nov. 25, 2014 (GLOBE NEWSWIRE) -- via PRWEB - Tango today announced it ranked 260 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest growing technology, media,...
-
Valmet Oyj:n lehdistötiedote 25.11.2014 klo 15:15 Valmet ja Nokianvirran Energia Oy ovat allekirjoittaneet aiesopimuksen biomassaa käyttävän kattilalaitoksen toimittamisesta uuteen...
-
Valmet Corporation's press release on November 25, 2014 at 3:15 p.m. EET Valmet and Nokianvirran Energia Oy have signed a letter of intent for a delivery of a biomass-fired boiler plant to a new...
-
100% of patients classified with Severidia® in the "good outcome" subgroup were alive after 2,500 days Improved p value (p < 10-5) NANCY, France, Nov. 25, 2014 (GLOBE NEWSWIRE)...
-
- Selinexor Synergy with DNA Damage Inducing Treatments Provides Potential for Improved Clinical Outcomes - - XPO1 Occupancy Assay Developed to Evaluate Selinexor Binding to its Target and...